Eli Lilly and Company faces a pivotal period with the upcoming retirement of Anne White, a key neuroscience leader set for ...

Eli Lilly (LLY) announced the upcoming retirement of Anne White, a pivotal figure in its neuroscience division, and entered a ...

Bristol Myers Squibb appointed Nathan Pennell, MD, PhD, FASCO, as SVP, worldwide head of medical affairs for hematology and oncology, effective August 18. Nucleus RadioPharma hired former Food and ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

Eli Lilly (LLY) stock in focus as the company's neuroscience chief Anne White retires, and the firm begins an executive ...

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...

Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience ...

Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with ...

Eli Lilly shares plunged about 14% in midday trading Thursday after the company reported less-than-stellar results of a new study of an experimental anti-obesity pill that is expected to become a ...

Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell short of expectations, boosting investor confidence in the Danish ...

Eli Lilly's pill candidate, orforglipron, led to 11% weight loss in a late-stage trial, far less than results from injectable obesity drugs.

Pill Causes Major Weight Loss in Eli Lilly Trial’s Results The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year.